Head-To-Head Review: Avita Medical (NASDAQ:RCEL) versus Glaukos (NYSE:GKOS)

Avita Medical (NASDAQ:RCEL) and Glaukos (NYSE:GKOS) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, earnings, valuation and risk.

Valuation and Earnings

This table compares Avita Medical and Glaukos”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Avita Medical	$75.63 million	5.44	-$48.59 million	($1.44)	-9.29
Glaukos	$507.44 million	19.77	-$187.69 million	($3.25)	-52.34

Avita Medical has higher earnings, but lower revenue than Glaukos. Glaukos is trading at a lower price-to-earnings ratio than Avita Medical, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

27.7% of Avita Medical shares are held by institutional investors. Comparatively, 99.0% of Glaukos shares are held by institutional investors. 2.2% of Avita Medical shares are held by company insiders. Comparatively, 5.9% of Glaukos shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Analyst Recommendations

This is a summary of recent recommendations for Avita Medical and Glaukos, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Avita Medical	1	1	5	0	2.57
Glaukos	1	1	13	0	2.80

Avita Medical currently has a consensus price target of $12.20, suggesting a potential downside of 8.79%. Glaukos has a consensus price target of $181.43, suggesting a potential upside of 6.67%. Given Glaukos’ stronger consensus rating and higher probable upside, analysts clearly believe Glaukos is more favorable than Avita Medical.

Profitability

This table compares Avita Medical and Glaukos’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Avita Medical	-56.96%	N/A	-78.53%
Glaukos	-30.68%	-6.37%	-4.78%

Volatility and Risk

Avita Medical has a beta of 1.99, indicating that its stock price is 99% more volatile than the S&P 500. Comparatively, Glaukos has a beta of 0.69, indicating that its stock price is 31% less volatile than the S&P 500.

Summary

Glaukos beats Avita Medical on 9 of the 14 factors compared between the two stocks.

About Avita Medical

AVITA Medical, Inc., together with its subsidiaries, operates as a regenerative medicine company in the United States and internationally. The company's lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds, full-thickness skin defects, and repigmentation of stable depigmented vitiligo lesions. It develops RECELL GO to control the manual process of disaggregation, filtration, and soak time. The company was formerly known as AVITA Therapeutics, Inc. AVITA Medical, Inc. was incorporated in 2020 and is headquartered in Valencia, California.

About Glaukos

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; and iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California.